| scholarly article | Q13442814 |
| P50 | author | Helena Barroso | Q55302937 |
| Inês Bártolo | Q56850073 | ||
| Pedro Borrego | Q56854274 | ||
| Pilar Garcia-Broncano | Q91496231 | ||
| Mª Ángeles Muñoz-Fernández | Q40088018 | ||
| Nuno Taveira | Q42305919 | ||
| Rui Pinto | Q43121437 | ||
| João F. Pinto | Q46925599 | ||
| P2093 | author name string | Carlos Cardoso | |
| João Pedro Ferreira | |||
| Maria Rosário Bronze | |||
| Ana Rita Diniz | |||
| Rafael Ceña Diaz | |||
| P2860 | cites work | Microflora changes with the use of a vaginal microbicide. | Q52545969 |
| Production of antimicrobial substances by lactic acid bacteria I: determination of hydrogen peroxide. | Q54505795 | ||
| [Role of pH as a regulator of vaginal physiological environment] | Q74018628 | ||
| The vaginal microbial ecosystem and resistance to HIV | Q74530837 | ||
| A study of the prevalence of hydrogen peroxide generating Lactobacilli in bacterial vaginosis: the determination of H2O2 concentrations generated, in vitro , by isolated strains and the levels found in vaginal secretions of women with and without in | Q80924860 | ||
| In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials | Q81352536 | ||
| Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health | Q21129223 | ||
| Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach | Q26859055 | ||
| A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice | Q28478394 | ||
| Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study | Q30384060 | ||
| An algorithm for the preclinical development of anti-HIV topical microbicides | Q30412043 | ||
| Tenofovir-based preexposure prophylaxis for HIV infection among African women | Q30621914 | ||
| A vaginal fluid simulant | Q33653706 | ||
| Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety | Q33880947 | ||
| Indigogenic substrates for detection and localization of enzymes | Q34004755 | ||
| Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety | Q34078011 | ||
| PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial | Q34138687 | ||
| Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women | Q34154701 | ||
| A review of the physical and chemical properties of human semen and the formulation of a semen simulant | Q34426459 | ||
| Preformulation studies as an essential guide to formulation development and manufacture of protein pharmaceuticals. | Q34791499 | ||
| In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis? | Q34933424 | ||
| Preformulation and stability in biological fluids of the retrocyclin RC-101, a potential anti-HIV topical microbicide | Q35426599 | ||
| The microbiota of the vagina and its influence on women's health and disease | Q35641829 | ||
| Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1 | Q35808786 | ||
| Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial | Q36048957 | ||
| Microbicidal spermicide or spermicidal microbicide? | Q36383005 | ||
| Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations | Q36837475 | ||
| Sexual communication self-efficacy, hegemonic masculine norms and condom use among heterosexual couples in South Africa. | Q36978253 | ||
| Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma | Q37051645 | ||
| Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women | Q37194802 | ||
| The current status of the use of oral medication to prevent HIV transmission | Q37212913 | ||
| Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS. | Q37255082 | ||
| A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus | Q37512840 | ||
| Microbicides and HIV prevention: lessons from the past, looking to the future | Q37633913 | ||
| Inhibition of HIV-1 by fusion inhibitors | Q37815514 | ||
| Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission | Q37856916 | ||
| Current Concepts for the IND-Directed Development of Microbicide Products to Prevent the Sexual Transmission of HIV. | Q38577624 | ||
| The Vaginal Microbiome: Current Understanding and Future Directions | Q38838623 | ||
| Baseline susceptibility of primary HIV-2 to entry inhibitors | Q38915512 | ||
| Carbosilane dendrimer nanotechnology outlines of the broad HIV blocker profile. | Q39339007 | ||
| Seminal plasma reduces the effectiveness of topical polyanionic microbicides | Q40070682 | ||
| A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety | Q40228392 | ||
| An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity | Q42713370 | ||
| Assessment of the Alamar Blue assay for cellular growth and viability in vitro | Q42800570 | ||
| Kinetic studies of the degradation of oxycarbonyloxymethyl prodrug of Adefovir and Tenofovir in solution | Q43741754 | ||
| Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis | Q44773914 | ||
| Fourteen-day safety and acceptability study of the universal placebo gel. | Q44926386 | ||
| Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial | Q46871110 | ||
| Methods for in vitro evaluating antimicrobial activity: A review | Q49240555 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e0195744 | |
| P577 | publication date | 2018-04-18 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women. | |
| P478 | volume | 13 |
Search more.